Prostate cancer risk unaffected by micronutrients
September 20th 2007Although previous studies suggest that high plasma concentrations of carotenoids, retinol, or tocopherols may reduce the risk of prostate cancer, recent research from Europe showed no associations between these micronutrients and overall prostate cancer risk. However, when study subjects were stratified by disease stage, both plasma lycopene and the sum of all measured plasma carotenoids were associated with reduced risk of advanced disease only.
Combination therapy promising for shrinking prostate tumors
September 20th 2007The monoclonal antibody bavituximab significantly shrank resistant human prostate tumors in mice when added to a standard regimen of androgen deprivation and docetaxel (Taxotere), according to researchers at the University of Texas Southwestern Medical Center in Dallas.
More prostate cancer screenings do not reduce aggressive disease
September 20th 2007More prostate cancers were detected among men who were screened every 2 years than among men screened every 4 years, according to a study published in an online edition of the Journal of the National Cancer Institute (2007; 99:1296-303). But the shorter time between screenings did not reduce the number of aggressive cancers found between the scheduled screening tests.
Combination therapy provides continuous BPH symptom improvement
September 20th 2007Combination treatment with the 5-alpha-reductase inhibitor dutasteride (Avodart) and the alpha-blocker tamsulosin (Flomax) provides significantly greater urinary symptom improvement for men with BPH than either therapy alone does over 24 months, according to a study presented at the recent meeting of the Société Internationale d’Urologie in Paris.
Sildenafil's effects may extend beyond sexual organs
September 6th 2007Sildenafil citrate (Viagra) may elevate the release of reproductive hormone, according to the authors of an animal study from the University of Wisconsin, Madison. The finding is potentially the first sign of a chemical means by which erectile dysfunction drugs may physically affect the body beyond heightening blood flow to sexual organs.
Urologists use single keyhole surgery to remove kidney
September 6th 2007Surgeons at the University of Texas Southwestern Medical Center, Dallas, effectively removed a patient's kidney by conducting an atypical nephrectomy, known as “single keyhole access” surgery, via the umbilicus. This marked the first such surgery that involved a kidney, and it required one incision.
Advocacy group to rally for prostate cancer therapy, FDA reform
September 6th 2007A cancer patient advocacy group said it will rally at FDA headquarters this month to ask FDA to reconsider its “flawed” decision on sipuleucel-T (Provenge), a form of immunotherapy under investigation for the treatment of late-stage prostate cancer.
Famed basketball coach tours nation to get word out on BPH
September 6th 2007The Prostate Cancer Education Council, a nonprofit consortium of expert physicians, health educators, scientists, and prostate health advocates, is teaming with former Detroit Pistons basketball coach Chuck Daly to spread the word on prostate health issues. BPH Game Plan Starts with U, the culmination of their efforts, is a recently launched national initiative to promote screenings and to raise awareness of BPH.
Younger brachytherapy patients likely to maintain long-term erectile function
September 6th 2007Prostate cancer patients younger than 60 years who had healthy erectile function (EF) prior to low doses of brachytherapy have a strong likelihood of sustaining long-term EF, according to a study by radiation oncologists and urologists at Mount Sinai School of Medicine in New York.
PDE-5 inhibitors may play a role in BPH, LUTS treatment
September 6th 2007The therapeutic role of phosphodiesterase type-5 inhibitors could expand to include some patients with BPH and lower urinary tract symptoms, according to findings from two studies presented at the AUA annual meeting in Anaheim, CA.
Molecule may signal onset, return of prostate cancer
September 6th 2007An immune molecule potentially responsible for the onset, return, and progression of prostate cancer has been discovered by researchers at the Mayo Clinic in Rochester, MN. The report on the B7-H3 molecule appeared in Cancer Research (2007; 67:7893-900).
Practical rules for calculating PSA doubling time
September 1st 2007PSA doubling time, defined as the length of time it takes for a PSA to double based on an exponential growth pattern, and PSA velocity, the rate of change of PSA over time, have been identified in large retrospective studies as strong prognostic indicators at the time of diagnosis prior to prostatectomy in patients with prostate cancer.
Biopsychosocial factors may help target CP/CPPS treatment
September 1st 2007Several novel biopsychosocial factors have been identified as significant independent predictors of lower quality of life in patients with chronic prostatitis/chronic pelvic pain syndrome, according to an analysis of data collected from men enrolled in the National Institutes of Health's Chronic Prostatitis Cohort Study.
Updated prostate cancer guidelines stress risk stratification
September 1st 2007A panel of urologists, oncologists, research specialists, and a statistician began meeting 5 years ago with the goal of updating the AUA guidelines for treating localized prostate cancer, last issued in 1995. After reviewing thousands of papers, the group released the updated guidelines at the AUA annual meeting in May.